U.S. District Court Issues Final Judgment in Favor of Mylan in Patent Infringement Litigation Against Sunovion's Brovana® Product
, /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the Southern District of has issued a Final Judgment and Order following a ruling by the Court of Appeals for the Federal Circuit in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. The Order states that five of Mylan's patents related to its Perforomist® Inhalation Solution are valid and enforceable. Further, the Order states that Sunovion's Brovana® product infringes each of those patents.
Mylan previously announced a settlement agreement with Sunovion resolving the litigation relating to Sunovion's Brovana® product. In , the U.S. District Court for the Southern District of issued a Final Judgment and Order stating that Sunovion has acknowledged that two Mylan patents related to its Perforomist® Inhalation Solution are valid, enforceable and infringed by Sunovion's Brovana® product.
As a result of the two Court Orders, all seven Mylan patents relating to Perforomist® have been upheld as valid and enforceable and infringed by Sunovion's Brovana® product.
Mylan CEO commented, "We have always believed in the strength and validity of the intellectual property protecting Perforomist, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease (COPD), currently in development. We are pleased to have prevailed in the appellate court and settled this litigation and that the Court's Order brings this matter to a close."
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.